References:
1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. Litzow MR, Sun Z, Paietta E,
et al. ECOG-ACRIN-E1910 NCTN clinical trial: A phase III randomized trial of blinatumomab for newly diagnosed
BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults. Presented at: 64th ASH Annual Meeting and
Exposition; December 10–13, 2022; New Orleans, LA. 3. Referenced with
permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute
Lymphoblastic Leukemia V.2.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed
July 22, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no
warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for
their application or use in any way. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Acute Lymphoblastic Leukemia V.1.2025. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 3, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.